Asia Pacific small molecule API market will grow by 8.7% annually with a total addressable market cap of over $1 trillion over 2023-2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasing technological developments in manufacturing sector, and a surging healthcare expenditure.
Highlighted with 67 tables and 51 figures, this 131-page report “Asia Pacific Small Molecule API Market 2022-2032 by Source (Synthetic, Semi-synthetic, Natural), Product Type (Standard, HPAPI), Therapeutic Area, Application (Clinical, Commercial), Manufacturer Type (Pharma, CMO), and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific small molecule API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule API market in every aspect of the classification from perspectives of Source, Product Type, Therapeutic Area, Application, Manufacturer Type, and Country.
Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Synthetic API
o Branded Synthetic API
o Generic Synthetic API
• Semi-synthetic API
• Natural Origin
Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Standard API
• High Potency API (HPAPI)
o Branded HPAPI
o Generic HPAPI
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas
By Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Clinical Use
• Commercial Use
By Manufacturer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.
• Pharmaceutical Companies
• CMOs
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Product Type, Therapeutic Area, and Manufacturer Type over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Aurobindo Pharma Ltd.
Cambrex Corporation
Catalent Inc.
Dr. Reddy's Laboratories
GlaxoSmithKline plc
Lonza Group
Merck & Co., Inc.
Mylan N.V.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Wuxi AppTec Co., Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 26
2.2 Major Growth Drivers 30
2.3 Market Restraints and Challenges 34
2.4 Emerging Opportunities and Market Trends 37
2.5 Porter’s Fiver Forces Analysis 41
3 Segmentation of Asia Pacific Market by Source 45
3.1 Market Overview by Source 45
3.2 Synthetic API 47
3.2.1 Branded Synthetic API 48
3.2.2 Generic Synthetic API 49
3.3 Semi-synthetic API 50
3.4 Natural Origin 51
4 Segmentation of Asia Pacific Market by Product Type 52
4.1 Market Overview by Product Type 52
4.2 Standard API 54
4.3 High Potency API (HPAPI) 55
4.3.1 Branded HPAPI 56
4.3.2 Generic HPAPI 57
5 Segmentation of Asia Pacific Market by Therapeutic Area 58
5.1 Market Overview by Therapeutic Area 58
5.2 Infectious Diseases 60
5.3 Oncology 61
5.4 Ophthalmology 62
5.5 Cardiovascular Disorders 63
5.6 Central Nervous System 64
5.7 Respiratory Disorders 65
5.8 Metabolic Diseases 66
5.9 Other Therapeutic Areas 67
6 Segmentation of Asia Pacific Market by Application 68
6.1 Market Overview by Application 68
6.2 Clinical Use 70
6.3 Commercial Use 71
7 Segmentation of Asia Pacific Market by Manufacturer Type 72
7.1 Market Overview by Manufacturer Type 72
7.2 Pharmaceutical Companies 74
7.3 CMOs 76
8 Asia-Pacific Market 2022-2032 by Country 78
8.1 Overview of Asia-Pacific Market 78
8.2 Japan 81
8.3 China 84
8.4 Australia 86
8.5 India 88
8.6 South Korea 90
8.7 Rest of APAC Region 92
9 Competitive Landscape 94
9.1 Overview of Key Vendors 94
9.2 New Product Launch, Partnership, Investment, and M&A 97
9.3 Company Profiles 98
Aurobindo Pharma Ltd. 98
Cambrex Corporation 100
Catalent Inc. 101
Dr. Reddy's Laboratories 104
GlaxoSmithKline plc 107
Lonza Group 111
Merck & Co., Inc. 114
Mylan N.V. 116
Novartis AG 118
Pfizer Inc. 120
Sun Pharmaceutical Industries Ltd. 124
Teva Pharmaceutical Industries Ltd. 127
Wuxi AppTec Co., Ltd. 129
RELATED REPORTS 131
List of Tables:
Table 1. Snapshot of Asia Pacific Small Molecule API Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 22
Table 3. World Economic Outlook, 2021-2023 23
Table 4. Scenarios for Economic Impact of Ukraine Crisis 27
Table 5. World Health Spending by Region, $ bn, 2013-2020 32
Table 6. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 33
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule API Market 37
Table 8. Asia Pacific Small Molecule API Market by Source, 2022-2032, $ mn 45
Table 9. Asia Pacific Small Molecule API Market: Synthetic API by Drug Type, 2022-2032, $ mn 47
Table 10. Asia Pacific Small Molecule API Market by Product Type, 2022-2032, $ mn 52
Table 11. Asia Pacific Small Molecule API Market: HPAPI by Drug Type, 2022-2032, $ mn 55
Table 12. Asia Pacific Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 58
Table 13. Asia Pacific Small Molecule API Market by Application, 2022-2032, $ mn 68
Table 14. Asia Pacific Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 72
Table 15. APAC Small Molecule API Market by Country, 2022-2032, $ mn 79
Table 16. Japan Small Molecule API Market by Product Type, 2022-2032, $ mn 83
Table 17. Japan Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 83
Table 18. Japan Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 83
Table 19. China Small Molecule API Market by Product Type, 2022-2032, $ mn 85
Table 20. China Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 85
Table 21. China Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 85
Table 22. Australia Small Molecule API Market by Product Type, 2022-2032, $ mn 87
Table 23. Australia Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 87
Table 24. Australia Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 87
Table 25. India Small Molecule API Market by Product Type, 2022-2032, $ mn 89
Table 26. India Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 89
Table 27. India Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 89
Table 28. South Korea Small Molecule API Market by Product Type, 2022-2032, $ mn 91
Table 29. South Korea Small Molecule API Market by Therapeutic Area, 2022-2032, $ mn 91
Table 30. South Korea Small Molecule API Market by Manufacturer Type, 2022-2032, $ mn 91
Table 31. Small Molecule API Market in Rest of APAC by Country/Region, 2022-2032, $ mn 93
Table 32. Aurobindo Pharma Ltd.: Company Snapshot 98
Table 33. Aurobindo Pharma Ltd.: Business Segmentation 99
Table 34. Aurobindo Pharma Ltd.: Product Portfolio 99
Table 35. Cambrex Corporation: Company Snapshot 100
Table 36. Catalent Inc.: Company Snapshot 101
Table 37. Catalent Inc.: Business Segmentation in 2018 101
Table 38. Catalent Inc.: Product Portfolio 102
Table 39. Catalent Inc.: Revenue, 2018-2020, $ million 102
Table 40. Catalent Inc.: Revenue by Region in 2018 103
Table 41. Dr. Reddy's Laboratories: Company Snapshot 104
Table 42. Dr. Reddy's Laboratories: Business Segmentation 104
Table 43. Dr. Reddy's Laboratories: Revenue, 2018-2020, $ bn 105
Table 44. GlaxoSmithKline: Company Snapshot 107
Table 45. GlaxoSmithKline: Business Segmentation 108
Table 46. GlaxoSmithKline: Product Portfolio 109
Table 47. GlaxoSmithKline: Revenue, 2018-2020, $ bn 110
Table 48. Lonza Group: Company Snapshot 111
Table 49. Lonza Group: Business Segmentation in 2018 111
Table 50. Lonza Group: Product Portfolio 112
Table 51. Lonza Group: Revenue by Region in 2018 112
Table 52. Merck & Co., Inc.: Company Snapshot 114
Table 53. Merck & Co., Inc.: Business Segmentation 114
Table 54. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 115
Table 55. Mylan NV: Company Snapshot 116
Table 56. Mylan NV: Revenue, 2017-2019, $ bn 117
Table 57. Novartis International AG: Company Snapshot 118
Table 58. Novartis International AG: Business Segmentation 118
Table 59. Novartis International AG: Revenue, 2017-2019, $ bn 119
Table 60. Pfizer Inc.: Company Snapshot 120
Table 61. Pfizer Inc.: Business Segmentation 121
Table 62. Pfizer Inc.: Product Portfolio 122
Table 63. Pfizer Inc.: Revenue, 2018-2020, $ bn 122
Table 64. Sun Pharmaceutical Industries Limited: Company Snapshot 124
Table 65. Teva Pharmaceutical Industries Ltd.: Company Snapshot 127
Table 66. Teva Pharmaceutical Industries Ltd.: Business Segmentation 128
Table 67. WuXi AppTec Inc.: Company Snapshot 129
